SANTA CRUZ BIOTECHNOLOGY, INC.

C18orf34 siRNA (h): sc-72683

BACKGROUND

C18orf34 (chromosome 18 open reading frame 34) is a 867 amino acid protein that is encoded by a gene that maps to human chromosome 18q12.1. Chromosome 18 houses over 300 protein-coding genes and contains nearly 76 million nucleotide bases. There are a variety of diseases associated with defects in chromosome 18-localized genes, some of which include Trisomy 18 (also known as Edwards syndrome), Niemann-Pick disease, hereditary hemorrhagic telangiectasia, erythropoietic protoporphyria and follicular lymphomas.

REFERENCES

1. Carstea, E.D., et al. 1993. Linkage of Niemann-Pick disease type C to human chromosome 18. Proc. Natl. Acad. Sci. USA 90: 2002-2004.
2. Petek, E., et al. 2003. Characterisation of a 19-year-old "long-term survivor" with Edwards syndrome. Genet. Couns. 14: 239-244.
3. Raghavan, S.C., et al. 2004. A non-B-DNA structure at the Bcl-2 major breakpoint region is cleaved by the RAG complex. Nature 428: 88-93.
4. Grosso, S., et al. 2005. Chromosome 18 aberrations and epilepsy: a review. Am. J. Med. Genet. A 134A: 88-94.
5. Aurizi, C., et al. 2007. Heterogeneity of mutations in the ferrochelatase gene in Italian patients with erythropoietic protoporphyria. Mol. Genet. Metab. 90: 402-407.
6. Broderick, P., et al. 2007. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat. Genet. 39: 1315-1317.
7. Kamal, A.H., et al. 2007. Hereditary hemorrhagic telangiectasia. Mayo Clin. Proc. 82: 1364.
8. Shovlin, C.L., et al. 2007. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb. Haemost. 98: 1031-1039.

CHROMOSOMAL LOCATION

Genetic locus: CCDC178 (human) mapping to 18q12.1.

PRODUCT

C18orf34 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 µM solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see C18orf34 shRNA Plasmid (h): sc-72683-SH and C18orf34 shRNA (h) Lentiviral Particles: sc-72683-V as alternate gene silencing products.

For independent verification of C18orf34 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-72683A, sc-72683B and sc-72683C.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 µl of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 µl of RNAse-free water makes a 10 µM solution in a 10 µM Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

C18orf34 siRNA (h) is recommended for the inhibition of C18orf34 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor C18orf34 gene expression knockdown using RT-PCR Primer: C18orf34 (h)-PR: sc-72683-PR (20 µl). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.